Stock JANX JANUX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
47.1 USD -0.86% Intraday chart for Janux Therapeutics, Inc. -3.72% +338.96%
May. 08 Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating MT
May. 08 Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Janux Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

dd1a5934ed8fe6f151a603495b.eXiq7feD8jmsGKokdz_ppewbtTGVkp2a6JnWnayuzew.QAKegrztqwHATcJALXiGzbR2gwLQ-MrMudWEzurIioUhFPq3h9axdsgq3Q~a59b30d4728e10b4f50fe273e66d8e4f

Analyst Recommendations on Janux Therapeutics, Inc.

Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating MT
JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target MT
BTIG Starts Janux Therapeutics With Buy Rating, $62 Price Target MT
Cantor Fitzgerald Starts Janux Therapeutics With Overweight Rating, $100 Price Target MT
H.C. Wainwright Adjusts Price Target on Janux Therapeutics to $50 From $35, Keeps Buy Rating MT
Wedbush Adjusts Janux Therapeutics' Price Target to $53 From $24; Keeps Outperform Rating MT
Health Care Up on Rate-Sensitive Sector Bias -- Health Care Roundup DJ
Wedbush Starts Janux Therapeutics at Outperform With $24 Price Target, See 'Attractive' Entry Point Ahead of Initial Clinical Data in H2 MT
William Blair Initiates Coverage for Janux Therapeutics With Outperform Rating MT
JANUX THERAPEUTICS : Evercore ISI Starts Janux Therapeutics at Outperform With $35 Price Target MT
JANUX THERAPEUTICS : BofA Securities Starts Janux Therapeutics at Buy With $35 Price Target MT
JANUX THERAPEUTICS : Cowen Initiates Coverage on Janux Therapeutics With Outperform Rating MT
JANUX THERAPEUTICS : HC Wainwright Starts Janux Therapeutics at Buy With $35 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
47.1 USD
Average target price
63.57 USD
Spread / Average Target
+34.97%
High Price Target
100 USD
Spread / Highest target
+112.31%
Low Price Target
25 USD
Spread / Lowest Target
-46.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Janux Therapeutics, Inc.

Wedbush
JonesTrading Institutional Services
BTIG
Cantor Fitzgerald
HC Wainwright
William Blair & Co.
Cowen
Evercore ISI
BofA Securities

Ratings for Janux Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. JANX Stock
  4. Consensus Janux Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW